Press Release: D. E. Shaw Research : D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly

NEW YORK, June 13, 2022 /PRNewswire/ -- D. E. Shaw Research (DESRES) today announced that it has entered into an exclusive global license agreement with Eli Lilly and Company (Lilly) for the clinical development and commercialization of DESRES's program of Kv1.3-targeted therapeutics for...